These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 31046703)

  • 1. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry.
    Cowen L; Mancini M; Martin A; Lucas A; Donovan JM
    BMC Neurol; 2019 May; 19(1):84. PubMed ID: 31046703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
    Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
    J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982-2001.
    Fox DJ; Kumar A; West NA; DiRienzo AG; James KA; Oleszek J;
    J Child Neurol; 2015 Jan; 30(1):21-6. PubMed ID: 24682290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Mixed-Method Study Exploring Patient-Experienced and Caregiver-Reported Benefits and Side Effects of Corticosteroid Use in Duchenne Muscular Dystrophy.
    Fischer R; Porter K; Donovan JM; Scavina MT; Armstrong N; Denger B; Hasham S; Peay H
    J Neuromuscul Dis; 2023; 10(4):593-613. PubMed ID: 37182893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 11. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
    Kim S; Campbell KA; Fox DJ; Matthews DJ; Valdez R;
    J Child Neurol; 2015 Sep; 30(10):1275-80. PubMed ID: 25414237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
    Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
    Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
    J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of muscle weakness in Duchenne muscular dystrophy.
    Rivera SR; Jhamb SK; Abdel-Hamid HZ; Acsadi G; Brandsema J; Ciafaloni E; Darras BT; Iannaccone ST; Konersman CG; Kuntz NL; McDonald CM; Parsons JA; Tesi Rocha C; Zaidman CM; Butterfield RJ; Connolly AM; Mathews KD
    PLoS One; 2020; 15(10):e0240687. PubMed ID: 33075081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroids in Duchenne muscular dystrophy: major variations in practice.
    Griggs RC; Herr BE; Reha A; Elfring G; Atkinson L; Cwik V; McColl E; Tawil R; Pandya S; McDermott MP; Bushby K
    Muscle Nerve; 2013 Jul; 48(1):27-31. PubMed ID: 23483575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
    Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
    J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of corticosteroids in muscular dystrophy: a critical appraisal.
    Angelini C
    Muscle Nerve; 2007 Oct; 36(4):424-35. PubMed ID: 17541998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.